Drugs / (+)-SJ000557733
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04709692 | Apr 2021 → Apr 2022 | Plasmodium falciparum malaria, Plasmodium vivax malaria | R. Kiplin Guy | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | (+)-SJ000557733 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04709692 ↗ |
| Route | Oral | “SJ733 will be administered orally once every day for three consecutive days” NCT04709692 ↗ |